These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19731257)

  • 21. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular control of the cell cycle in cancer: biological and clinical aspects.
    Møller MB
    Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
    Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
    Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p16INK4a modulates p53 in primary human mammary epithelial cells.
    Zhang J; Pickering CR; Holst CR; Gauthier ML; Tlsty TD
    Cancer Res; 2006 Nov; 66(21):10325-31. PubMed ID: 17079452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
    Rampias T; Sasaki C; Weinberger P; Psyrri A
    J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
    Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
    Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status.
    Derenzini M; Ceccarelli C; Santini D; Taffurelli M; Treré D
    J Clin Pathol; 2004 Jul; 57(7):755-61. PubMed ID: 15220371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
    Gavressea T; Kalogeras KT; Koliou GA; Zagouri F; Lazaridis G; Gogas H; Tsigaridas K; Koutras A; Petraki K; Markopoulos C; Pazarli E; Aravantinos G; Papadimitriou C; Papakostas P; Koufopoulos N; Karanikiotis C; Chrisafi S; Kalofonos HP; Pectasides D; Fountzilas G; Pavlakis K
    Anticancer Res; 2017 Jun; 37(6):2947-2957. PubMed ID: 28551632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
    Treré D; Brighenti E; Donati G; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Derenzini M
    Ann Oncol; 2009 Nov; 20(11):1818-23. PubMed ID: 19556322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
    Chien WW; Catallo R; Chebel A; Baranger L; Thomas X; Béné MC; Gerland LM; Schmidt A; Beldjord K; Klein N; Escoffre-Barbe M; Leguay T; Huguet F; Larosa F; Hayette S; Plesa A; Ifrah N; Dombret H; Salles G; Chassevent A; Ffrench M
    Leuk Res; 2015 Apr; 39(4):453-61. PubMed ID: 25675863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.
    Zheng G; Xiong Y; Yi S; Zhang W; Peng B; Zhang Q; He Z
    FEBS Lett; 2012 Jan; 586(2):163-8. PubMed ID: 22192357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
    Knappskog S; Berge EO; Chrisanthar R; Geisler S; Staalesen V; Leirvaag B; Yndestad S; de Faveri E; Karlsen BO; Wedge DC; Akslen LA; Lilleng PK; Løkkevik E; Lundgren S; Østenstad B; Risberg T; Mjaaland I; Aas T; Lønning PE
    Mol Oncol; 2015 Oct; 9(8):1553-64. PubMed ID: 26004085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.